Corvus Pharmaceuticals (Corvus Pharmaceuticals) Asset Impairment Charge

: $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

Corvus Pharmaceuticals's Asset Impairment Charge for the three months ended in Dec. 2023 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil.

Corvus Pharmaceuticals Asset Impairment Charge Historical Data

The historical data trend for Corvus Pharmaceuticals's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Corvus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Corvus Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Asset Impairment Charge																-	-	-	-	-

Corvus Pharmaceuticals Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Corvus Pharmaceuticals Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Corvus Pharmaceuticals (Corvus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corvus Pharmaceuticals Inc (NAS:CRVS) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

C17:Germany

Address

863 Mitten Road, Suite 102, Burlingame, CA, USA, 94010

Website

https://www.corvuspharma.com

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the most critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers and autoimmune diseases. The company's lead product candidate is CPI-006 which is a potent humanized monoclonal antibody that is designed to react with a specific site on CD73. Its other product candidates are CPI-818, CPI-935, CPI-182 and Ciforadenant.

Executives

Linda S Grais	director	86 ALEJANDRA AVE, ATHERTON CA 94027
William Benton Jones	officer: See Remarks	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Leiv Lea	officer: Chief Financial Officer	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Miller Richard A Md	director, officer: President and CEO	PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Peter A. Thompson	director, 10 percent owner	C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545
Orbimed Advisors Llc	director	601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Edith P. Mitchell	director	1640 MARENGO ST., LOS ANGELES CA 90033
Novo Holdings A/s	10 percent owner	TUBORG HAVNEVEJ 19, HELLERUP G7 2900
Mehrdad Mobasher	officer: Chief Medical Officer	863 MITTEN ROAD, BURLINGAME CA 94010
Adams Street Partners Llc	10 percent owner	ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807
Terry P Gould	director, 10 percent owner	C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Joseph J Buggy	officer: EVP Discovery Research	CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Daniel W. Hunt	officer: SVP, Chief Business Officer	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Erik J. Verner	officer: V.P., Chemistry Research	863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010